SMA type 1 children show lasting benefits after 5 years on oral treatment
After five years of daily treatment with Evrysdi (risdiplam), 90% of children with spinal muscular atrophy (SMA) type 1 were alive, and most had reached motor milestones, such as sitting without support,…